New Triple-Threat attack on tough colon cancer
NCT ID NCT05722327
Summary
This early-stage trial is testing the safety and best dose of a new drug, adagrasib, when combined with two existing cancer drugs (cetuximab and irinotecan). It is for adults with advanced colorectal cancer that has a specific genetic change called KRAS G12C and has stopped responding to at least two prior treatments. The main goal is to see if this three-drug combination can help control the cancer while managing side effects.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COLON CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.